Vision Therapy
MA48/AcuNOVA Acupuncture
The MA48 previously known as AcuNova, is a type of
acupuncture treatment that is showing remarkable results
for people with eye diseases. Kathleen received her
masters training and certification in treating eyes from
Dr. Andy Rosenfarb who has treated complicated eye
conditions with the MA48 system with great success for
over 15 years.
Treatment involves newly discovered points at the hands
and feet that are not associated with any other acupuncture
system. Two points also used are located in the eyebrows and studies show that these points increase blood circulation to the retina in the eye. 85% of patients respond to treatment, depending on the type of eye disease.
To maintain improvement, patients then receive maintenance on either a monthly, quarterly or yearly treatment plan in order to maintain their improvement.
Eye Conditions
At Point Balance Acupuncture LLC, we specialize in treating degenerative eye diseases as well as other serious eye conditions utilizing an integrated, whole-body health approach that combines Acupuncture, Traditional Chinese Medicine, nutritional recommendations and other cutting-edge therapies.
We treat:
-
Stargardt’s Syndrome
-
Retinal Detachment
-
Diabetic Retinopathy
-
Cataracts
-
Lazy Eye
-
Uveitis
-
Retinal Occlusion
-
Dry Eyes
If you have questions about whether or not your eye condition can be treated with the AcuNova system, call our office today to schedule a consultation. We are happy to talk to you about your options.
About Dr. Rosenfarb & the AcuNova Research
Dr. Rosenfarb teamed with researchers at Johns Hopkins University on the first ever clinical study to determine the efficacy of treating Retinitis Pigmentosa with acupuncture and other TCM therapies. Dr. Rosenfarb drew on his extensive training and clinical experience to develop the treatment protocol and trained staff at Johns Hopkins University to administer it to study participants.
Based on the success of that initial study, the NIH is funded a second, expanded clinical study in 2014 that once again utilize Dr. Rosenfarb’s treatment protocol. The first peer-reviewed study was recently published in Clinical and Experimental Optometry.
To view the study, click here.
